The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.
Yunokawa M, Abe A, Wang X, Toyohara Y, Nimura R, Komoto T, Misaka S, Yoshimitsu T, Ikki A, Kamata M, Nishino S, Kanno M, Fusegi A, Netsu S, Aoki Y, Omi M, Tanigawa T, Okamoto S, Nomura H, Kanao H.
Yunokawa M, et al. Among authors: wang x.
Int J Clin Oncol. 2024 Dec 6. doi: 10.1007/s10147-024-02667-0. Online ahead of print.
Int J Clin Oncol. 2024.
PMID: 39641902